Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 703 clinical trials
None
A Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas

Study CC-90010-ST-001 is an open-label, Phase 1a, dose escalation and expansion, First-in-human (FIH) clinical study of CC-90010 in subjects with advanced or unresectable solid tumors and relapsed and/or refractory advanced Non-Hodgkin's lymphoma (NHL). The dose escalation part (Part A) of the study will explore escalating oral doses of CC-90010 to …

lymphoma
treatment regimen
measurable disease
large b-cell lymphoma
solid neoplasm
  • 160 views
  • 27 Aug, 2021
  • 14 locations
None
A Safety and Efficacy Study of CC-90011 in Subjects With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas

Study CC-90011-ST-001 is an open-label, Phase 1, dose escalation and expansion, First-In-Human (FIH) clinical study of CC-90011 in subjects with advanced unresectable solid tumors (enriched for grade 2 NENs, grade 2 NETs and NECs) and R/R NHL (MZL, including extranodal MZL [EMZL], splenic MZL [SMZL], nodal MZL [NMZL], and histologic …

lymphoma
growth factor
lung cancer
blood transfusion
solid neoplasm
  • 0 views
  • 08 Jan, 2022
  • 14 locations
None
EXOME Analysis Position in the Strategy of Genetic Predisposition Factors Identification in Early-onset Cancer

5 to 10% of cancers are due to the presence of a constitutional genetic alteration. It can be inherited from parents (family form) or by accident, in the first moments of life after fertilization (sporadic form). In both cases, this genetic alteration is constitutional and transmissible to descendants. It is …

breast cancer
primary cancer
  • 0 views
  • 23 Jan, 2021
  • 7 locations
None
Analysis of Circulating Tumor Markers in Blood

The circulating tumoral biomarkers in the blood are the object of numerous researches for several decades. The potential clinical interests of these circulating biomarkers are diagnostic, prognostic, predictive of the efficiency of targeted therapies (according to the mutational profile of the cancer), and could allow the study of the mechanisms …

tumor markers
primary cancer
  • 2 views
  • 10 Nov, 2021
  • 2 locations
None
A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors

To evaluate MEDI1191 administered intratumorally in sequential and concurrent combination with intravenous durvalumab in patients with solid tumors.

solid tumour
solid tumor
corticosteroids
solid neoplasm
metastasis
  • 15 views
  • 11 Dec, 2021
  • 15 locations
None
Predictive Markers of Immune-related Adverse Events in Patients Treated With Immune Stimulatory Drugs

The prospect of effective immunotherapies for the treatment of patients with cancer is now a clinical reality thanks to the approval of monoclonal antibodies (mAbs) specifically blocking immune checkpoints or ligands such as CTLA-4, PD-1 and PD-L1. However, these drugs can also induce inflammatory and/or auto-immune complications (Immune-related Adverse Events; …

immunosuppressive agents
primary cancer
pd-l1
combinations
monoclonal antibodies
  • 0 views
  • 22 Jan, 2021
None
A Study to Evaluate Safety Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients

This is a first in human study to identify whether FP-1305 is suitable to use in humans. The previous pre-clinical studies have demonstrated that FP-1305 binds to a receptor known as CLEVER-1. CLEVER-1 has been shown to support tumour growth. No significant adverse events were witnessed in primates and the …

primary cancer
exhaustion
breast cancer
platelet count
measurable disease
  • 4 views
  • 19 Nov, 2021
  • 12 locations
None
Influence of PARAmedical Interventions on Patient ACTivation in the Cancer Care Pathway

The aim is to implement the Patient Activation Measure in paramedical practices as a tool to measure activation of patients in cancer care

primary cancer
cancer care
  • 0 views
  • 29 Jan, 2021
  • 13 locations
None
An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer

This study is being done to determine the efficacy and safety of cofetuzumab pelidotin in the PTK7-expressing, recurrent non-small cell lung cancer (NSCLC) population.

solid tumour
primary cancer
systemic therapy
recurrent non-small cell lung cancer
cancer chemotherapy
  • 6 views
  • 20 Dec, 2021
  • 38 locations
None
Caregivers' and Cancer Survivors' Psychological Distress & Symptom Management

Sample: The sample will be 298 ethnically diverse (30% Hispanic) survivors who have a new diagnosis or localized recurrence of solid tumor cancer and elevated depression or anxiety and their informal caregivers. Design: The investigators selected the SMART design for this study over alternative designs (e.g.,implementation designs) because the SMART …

solid tumor
hormone therapy
primary cancer
targeted therapy
endocrine therapy
  • 0 views
  • 25 Feb, 2021
  • 1 location